Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsPreferred Shares IssuedProperty, Plant & Equipment (Gross)Receivables - Other
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Receivables - Other (2016 - 2025)

Viridian Therapeutics, Inc.\DE has reported Receivables - Other over the past 8 years, most recently at $70.0 million for Q3 2025.

  • Quarterly results put Receivables - Other at $70.0 million for Q3 2025, up 499900.0% from a year ago — trailing twelve months through Sep 2025 was $70.0 million (up 499900.0% YoY), and the annual figure for FY2023 was $102000.0, changed 0.0%.
  • Receivables - Other for Q3 2025 was $70.0 million at Viridian Therapeutics, Inc.\DE, up from $14000.0 in the prior quarter.
  • Over the last five years, Receivables - Other for VRDN hit a ceiling of $70.0 million in Q3 2025 and a floor of $14000.0 in Q3 2024.
  • Median Receivables - Other over the past 5 years was $128000.0 (2023), compared with a mean of $5.6 million.
  • Biggest five-year swings in Receivables - Other: tumbled 86.27% in 2024 and later surged 499900.0% in 2025.
  • Viridian Therapeutics, Inc.\DE's Receivables - Other stood at $451000.0 in 2021, then plummeted by 77.38% to $102000.0 in 2022, then changed by 0.0% to $102000.0 in 2023, then tumbled by 86.27% to $14000.0 in 2024, then surged by 499900.0% to $70.0 million in 2025.
  • The last three reported values for Receivables - Other were $70.0 million (Q3 2025), $14000.0 (Q3 2024), and $102000.0 (Q1 2024) per Business Quant data.